98 related articles for article (PubMed ID: 15114711)
1. [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Hada M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):613-7. PubMed ID: 15114711
[TBL] [Abstract][Full Text] [Related]
2. [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Hada M; Mizutari K
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1407-10. PubMed ID: 15446566
[TBL] [Abstract][Full Text] [Related]
3. [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
Hada M; Kazuhiro M
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2191-4. PubMed ID: 15628770
[TBL] [Abstract][Full Text] [Related]
4. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Natale RB
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Fujita A; Takabatake H; Tagaki S; Sekine K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1987-91. PubMed ID: 9350247
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
[TBL] [Abstract][Full Text] [Related]
8. [Intrathoracic infusion with a combination of low-dose minocycline, OK-432 and cisplatin for malignant pleural effusion].
Ishimori S; Okada S; Yamagata S; Satoh S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):345-9. PubMed ID: 15791817
[TBL] [Abstract][Full Text] [Related]
9. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
11. [A case of small-cell lung cancer responding remarkably to CPT-11 and CDDP combination chemotherapy].
Ishiura Y; Terasaki Y; Nakamura H; Yokawa S; Saito K; Kasahara K; Fujimura M
Gan To Kagaku Ryoho; 2006 Mar; 33(3):369-71. PubMed ID: 16531721
[TBL] [Abstract][Full Text] [Related]
12. Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin.
Jiang L; Li P; Gong Z; Hu B; Ma J; Wang J; Chu H; Zhang L; Sun P; Chen J
Anticancer Res; 2016 Mar; 36(3):1313-8. PubMed ID: 26977031
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the therapeutic effects of pleural perfusion of NDP and cDDP in NSCLC patients with malignant pleural effusion].
Cong YY; Liu MY; Cai L
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):467-9. PubMed ID: 20819493
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Pan CX; Loehrer P; Seitz D; Helft P; Juliar B; Ansari R; Pletcher W; Vinson J; Cheng L; Sweeney C
Oncology; 2005; 69(1):63-70. PubMed ID: 16088234
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the prognosis of 111 patients with gastric cancer or adenocarcinoma of the esophagogastric junction combined with pleural or abdominal effusion].
Liu Y; Du CX; Zhang HG
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):693-7. PubMed ID: 24332058
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Trifan OC; Durham WF; Salazar VS; Horton J; Levine BD; Zweifel BS; Davis TW; Masferrer JL
Cancer Res; 2002 Oct; 62(20):5778-84. PubMed ID: 12384538
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.
Nio Y; Nagami H; Tamura K; Tsubono M; Nio M; Sato M; Kawabata K; Hayashi H; Shiraishi T; Imai S; Tsuchitani T; Mizuta J; Nakagawa M; Fukumoto M
Br J Cancer; 1999 May; 80(5-6):775-85. PubMed ID: 10360655
[TBL] [Abstract][Full Text] [Related]
18. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
[TBL] [Abstract][Full Text] [Related]
19. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
Yeo KT; Wang HH; Nagy JA; Sioussat TM; Ledbetter SR; Hoogewerf AJ; Zhou Y; Masse EM; Senger DR; Dvorak HF
Cancer Res; 1993 Jun; 53(12):2912-8. PubMed ID: 8504432
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Dy GK; Mandrekar S; Peethambaram PP; Okuno SH; Croghan GC; Hanson LJ; Furth A; Adjei AA
Cancer Chemother Pharmacol; 2005 Dec; 56(6):623-8. PubMed ID: 15999272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
